efficacy of parp inhibitors in the treatment of aml
Published 2 years ago • 132 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
7:27
menin inhibitors in aml: mechanism of action, the current key data, and predicting efficacy
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
2:34
the evolution of the aml treatment paradigm
-
1:14
promising novel agents in aml: menin inhibitors
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
1:56
the efficacy of olutasidenib in patients with r/r idh-mutant aml
-
29:51
finding the key to better outcomes in flt3-mutated aml
-
4:36
haemonetics
-
7:46
updates in aml treatment and research from asco 2023
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
2:09
advances in the management of fit adults with aml
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml